Last reviewed · How we verify
DT-Polio®
DT-Polio is a combined diphtheria-tetanus-poliomyelitis vaccine that stimulates the immune system to produce antibodies against diphtheria toxin, tetanus toxin, and poliovirus.
DT-Polio is a combined diphtheria-tetanus-poliomyelitis vaccine that stimulates the immune system to produce antibodies against diphtheria toxin, tetanus toxin, and poliovirus. Used for Prevention of diphtheria, tetanus, and poliomyelitis in pediatric and adult populations.
At a glance
| Generic name | DT-Polio® |
|---|---|
| Sponsor | Sanofi Pasteur, a Sanofi Company |
| Drug class | Combination vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
The vaccine contains inactivated or toxoid forms of diphtheria and tetanus antigens along with inactivated poliovirus particles. Upon administration, these antigens trigger both humoral and cellular immune responses, leading to the production of protective antibodies (primarily IgG) against these three pathogens. This provides immunological memory that protects against future exposure to wild-type diphtheria, tetanus, and poliovirus.
Approved indications
- Prevention of diphtheria, tetanus, and poliomyelitis in pediatric and adult populations
Common side effects
- Injection site pain, erythema, or swelling
- Fever
- Myalgia or fatigue
- Headache
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- DT-Polio® CI brief — competitive landscape report
- DT-Polio® updates RSS · CI watch RSS
- Sanofi Pasteur, a Sanofi Company portfolio CI